| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_5882b9b33b37e3a5756219f603e4af8e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_37f4922dfb7777b019e504b885211b8e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b01dcd61775e996fac631d4b10c4e87f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a14a672c764e6ae9c4b633c1d9614f19
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c5073a0063d6be9e25c14d2af0a1ee89
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d44689d6c45d029dce7bd8bd66043414 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-17 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-17
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P27-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-14 |
| filingDate |
2016-08-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0ac4d3bcb3353ac2a3089eaf84caaef3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f8d5372208cd7c0bf51bf2d9298fc075
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2e416e233bd111b002e700d9e266c5b8
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_acec17dceaeaf2b0ea0b2999392fbd11
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cb6718ae023cde63fc3aae17a817168b |
| publicationDate |
2018-08-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2018221313-A1 |
| titleOfInvention |
Use of hydroxycarbamide for preventing retinal nonperfusion |
| abstract |
The present invention relates to the use of hydroxycarbamide (HC) for reducing and/or delaying the extension of capillary nonperfusion, a cause of irreparable visual impairment in patients suffering from central retinal vein occlusion (CRVO). This is the first systemic treatment which makes it possible to reduce retinal ischemic complications in patients in whom (CRVO) has been recently diagnosed and is consequently in a rapidly progressive phase. Given the low toxicity of HC evaluated on a large scale in children and adults in the context of other diseases for decades, the results of the present study open up a new therapeutic approach in the treatment of CRVO. |
| priorityDate |
2015-08-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |